Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
CANTON, Mass., March 10, 2016 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Tuesday, March 15, 2016 at 7:30 a.m. ET. The Company will discuss its financial results for 2015 and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (866) 864-3220 (U.S.) or (704) 908-0478 (International). An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]
